RAPT Therapeutics, Inc. financial data

Symbol
RAPT on Nasdaq
Industry
Pharmaceutical Preparations
Location
561 Eccles Avenue, South San Francisco, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
FLX Bio, Inc. (to 1/2/2019)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 878 % -38.4%
Debt-to-equity 15.3 % +47.1%
Return On Equity -72.6 % -67.9%
Return On Assets -63 % -60.8%
Operating Margin -5.62 K % -210%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.8 M shares +1.49%
Common Stock, Shares, Outstanding 34.4 M shares +0.42%
Entity Public Float 399 M USD +25.1%
Common Stock, Value, Issued 3 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.6 M shares +0.9%
Weighted Average Number of Shares Outstanding, Diluted 38.6 M shares +0.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 100 M USD +31.9%
General and Administrative Expense 27.8 M USD +29.5%
Operating Income (Loss) -128 M USD -32.6%
Nonoperating Income (Expense) 9.97 M USD +153%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -117 M USD -39.3%
Net Income (Loss) Attributable to Parent -118 M USD -27.4%
Earnings Per Share, Basic -3.08 USD/shares -16.2%
Earnings Per Share, Diluted -3.08 USD/shares -16.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.3 M USD -0.99%
Marketable Securities, Current 96.3 M USD -48.2%
Cash, Cash Equivalents, and Short-term Investments 142 M USD
Assets, Current 148 M USD -36.8%
Property, Plant and Equipment, Net 2.24 M USD -25.3%
Operating Lease, Right-of-Use Asset 4.77 M USD -26.9%
Other Assets, Noncurrent 447 K USD -89.4%
Assets 156 M USD -37.3%
Accounts Payable, Current 6.77 M USD -24.3%
Accrued Liabilities, Current 11.8 M USD +14.1%
Liabilities, Current 21.2 M USD -2.04%
Operating Lease, Liability, Noncurrent 3.82 M USD -38.9%
Liabilities 25 M USD -10.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10 K USD -103%
Retained Earnings (Accumulated Deficit) -515 M USD -29.7%
Stockholders' Equity Attributable to Parent 131 M USD -40.7%
Liabilities and Equity 156 M USD -37.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.1 M USD -45.6%
Net Cash Provided by (Used in) Financing Activities 9.04 M USD +7690%
Net Cash Provided by (Used in) Investing Activities 15.9 M USD -37.2%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 34.4 M shares +0.42%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.16 M USD -132%
Deferred Tax Assets, Valuation Allowance 107 M USD +32.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 108 M USD +31.6%
Operating Lease, Liability 6.91 M USD -23.2%
Payments to Acquire Property, Plant, and Equipment 105 K USD -86.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -118 M USD -29.8%
Lessee, Operating Lease, Liability, to be Paid 7.65 M USD -26.1%
Property, Plant and Equipment, Gross 11.9 M USD +3.21%
Operating Lease, Liability, Current 2.51 M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.66 M USD -6.76%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.86 M USD +5.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 748 K USD -45.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.14 M USD -19.7%
Deferred Tax Assets, Operating Loss Carryforwards 58.2 M USD +10.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50 M shares 0%
Unrecognized Tax Benefits 4.67 M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.14 M USD -5.4%
Operating Lease, Payments 2.7 M USD +28.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 18.4 M USD +45.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%